The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Tigecycline: First of a New Class of Antimicrobial Agents
Abstract
Tigecycline is the first commercially available member of the glycylcyclines, a new class of antimicrobial agents. The glycylcyclines are derivatives of the tetracycline antibiotics, with structural modifications that allow for potent gram‐positive, gram‐negative, and anaerobic activity, including certain multidrug‐resistant strains. The enhanced activity can be attributed to stronger binding affinity and enhanced protection against several mechanisms of resistance that affect other antibiotic classes such as tetracyclines. Tigecycline exhibits generally bacteriostatic action by reversibly binding to the 30S ribosomal subunit and inhibiting protein translation. In vitro activity has been demonstrated against multidrug‐resistant gram‐positive pathogens including methicillin‐resistant and glycopeptide‐intermediate and ‐resistant Staphylococcus aureus, as well as vancomycin‐resistant enterococci. Multidrug‐resistant gram‐negative pathogens, such as Acinetobacter baumannii and extended‐spectrum β‐lactamase–producing Klebsiella pneumoniae and Escherichia coli, are typically highly susceptible to tigecycline. The drug also has displayed significant activity against many clinically important anaerobic organisms. This agent demonstrates a predictable pharmacokinetic profile and minimal drug interactions, and is generally well tolerated, with nausea being the most common adverse event. It was approved in June 2005 for the treatment of complicated skin and skin structure infections (SSSIs) and complicated intraabdominal infections. Currently, a limited number of broad‐spectrum antimicrobials are available to combat multidrug‐resistant organisms. The addition of new agents is essential to limiting the spread of these pathogens and improving outcomes in patients with these types of infections. Tigecycline has demonstrated promising results in initial in vitro and clinical studies for SSSIs and complicated intraabdominal infections; however, further clinical experience will clarify its role as a broad‐spectrum agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
Hiramatsu, K. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.1.135 · Cited by 1,984
Efflux-Mediated Resistance to Tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1
Dean, C. R., Visalli, M. A., Projan, S. J., Sum, P.-E., & Bradford, P. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.972-978.2003 · Cited by 286
Visalli, M. A., Murphy, E., Projan, S. J., & Bradford, P. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.2.665-669.2003 · Cited by 165
Cited by
David, M. Z., & Daum, R. S. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00081-09 · Cited by 1,972
Lee, C.-R., Lee, J. H., Park, K. S., Kim, Y. B., Jeong, B. C., & Lee, S. H. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00895 · Cited by 739
Yaghoubi, S., Zekiy, A. O., Krutova, M., Gholami, M., Kouhsari, E., Sholeh, M., Ghafouri, Z., & Maleki, F. (2022) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-04121-1 · Cited by 332
History of antimicrobial drug discovery: Major classes and health impact
Aminov, R. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.10.001 · Cited by 296
Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis
Tasina, E., Haidich, A.-B., Kokkali, S., & Arvanitidou, M. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70177-3 · Cited by 260
Pangenomes of human gut microbiota uncover links between genetic diversity and stress response
Shoer, S., Reicher, L., Zhao, C., Pollard, K. S., Pilpel, Y., & Segal, E. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.08.017 · Cited by 23
Metadata
- Authors
- Rose, W. E., & Rybak, M. J.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2006-08
- Volume
- 26
- Issue
- 8
- Pages
- 1099-1110
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2006021893
- Cited by
- 195
- References
- 3
- FWCI
- 5.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.